Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population
Introduction
A growing number of studies suggest a causative relationship between antipsychotic treatment and metabolic disturbances. The most frequent problems linked to antipsychotic drugs have been abnormalities of glucose metabolism like insulin resistance, hyperglycemia or new onset diabetes mellitus and dyslipidemia, including increased levels of total cholesterol, LDL-cholesterol and triglycerides.
Compared with the general population it has been consistently found that patients with schizophrenia have a higher risk of diabetes (Holt et al., 2005). But it is unclear if it is the schizophrenia per se, the associated less healthy lifestyle or the antipsychotic treatment which is the factor that confers a higher risk of diabetes on these patients. The attribution mainly to antipsychotic drugs is based on the recent studies reporting higher rates of metabolic abnormalities coinciding with the introduction of the second generation agents. But we have to take into account that in the last years the incidence of diabetes in the general population has notably increased as well (Engelgau et al., 2004). In addition, the quality of health care of the psychiatric population has improved and therefore these subjects are more likely to have glucose testing.
There are conflicting results in the published literature (Holt and Peveler, 2006). Most epidemiological studies have shown that diabetes is more frequent in patients having antipsychotics than in non-treated patients (Gianfrancesco et al., 2006, Ramaswamy et al., 2006)—especially in those treated with second generation drugs. On the contrary, prospective randomized clinical trials with placebo control groups have not found significant differences at short (Marder et al., 2003) or medium term (Beasley et al., 2003). The causal mechanism has not been established. There is no clear evidence to support that antipsychotics cause a direct toxic effect on peripheral tissues. The weight gain induced by antipsychotics has been proposed as a potential mechanism by which these drugs may increase the risk for insulin resistance, hyperglycemia and dyslipidemia. However, it seems that not all the cases of glucose dysregulation can be explained by weight increase (Jin et al., 2002). Several recent studies have focused on the receptor-binding profiles of antipsychotics to explain their differences in side effects but still the mechanisms are not well understood (Nasrallah, 2008).
Prospective long-term studies in drug-naïve first episode psychosis patients could contribute towards clarifying of the link between antipsychotic therapy and metabolic side effects. There are some advantages in this study population. Firstly, there is no carry-over effect of previous treatments. Secondly, the effect of the illness on lifestyle is expected to be minimal in these early stages. Thirdly, to detect an impairment in glucose or lipid metabolism a long term follow-up is required.
In this study we examined several parameters of glucose and lipid metabolism in fasting conditions before and after the first year of exposure to antipsychotic treatment in a population of drug-naïve patients with first episode of psychosis. Secondarily, we compared the effect of three randomly assigned antipsychotic drugs (haloperidol, olanzapine and risperidone) on metabolic parameters. Finally we studied the relationship between weight gain and changes in metabolic parameters.
Section snippets
Method
This study was conducted in the outpatient and inpatient psychiatric units of Marques de Valdecilla University Hospital, located in the province of Cantabria, in the north of Spain. The hospital is a reference centre of a catchment area population of 555,000 people and provides the only psychiatric acute inpatient unit and 24 h emergency care service for the whole province. To guarantee the inclusion of all first episodes of psychosis regular meetings with all Mental Health Care services of
Enrolment and characteristics of study population
From February 2001, 225 subjects were screened. Of these, 59 were excluded for not meeting the inclusion criteria and two refused to participate in the study. A total of 164 patients were included and randomized to receive: haloperidol (52), olanzapine (54) and risperidone (58). We had a 12% dropout rate at 1 year (18 patients were lost to follow up and two patients refused to be evaluated). Finally 144 patients were included in the analysis to assess weight gain [for more details see (
Discussion
After the first year of exposure to antipsychotic treatment a statistically significant increase in the mean values of insulin levels, insulin resistance index, total cholesterol, LDL-cholesterol, triglycerides and weight was found. These changes resulted clinically in a significantly higher proportion of subjects with obesity (4.3% to 22.6%) and a higher proportion of subjects with hypertriglyceridemia (4.9% to 18.3%). None of the patients developed diabetes.
The values observed in fasting
Role of funding source
The present study was performed at the Hospital Marques de Valdecilla, University of Cantabria, Santander, Spain, under the following grant support: Instituto de Salud Carlos III, FIS 00/3095 and SENY Foundation Research Grant CI 2005-0308007, Fundacion Marques de Valdecilla A/02/07.
No pharmaceutical company supplied financial support.
Contributors
All the authors have participated and have made substantial contributions to this paper:
Rocio Perez-Iglesias: design, analysis and interpretations of data and, drafting the article.
Benedicto Crespo-Facorro and Jose Luis Vazquez-Barquero: conception, design and revising.
Ignacio Mata, Obdulia Martinez-Garcia, Ana Berja, Jose Maria Pelayo-Teran: collection and interpretation of data.
Jose Antonio Amado and Maria Teresa Garcia-Unzueta: interpretation of data and revising.
They have read and approved
Conflict of interest
All authors declare they have NO conflicts of interest.
Financial disclosure
We have no affiliation or financial or other relationships with any organization or entity with a financial interest in or in financial competition with the subject matter or materials discussed in the manuscript.
Acknowledgements
We wish to thank the PAFIP researchers who helped with data collection and assistance during the investigations. In addition, we acknowledge the study participants and their families for enrolling in this study.
References (33)
- et al.
Early treatment-related changes in diabetes and cardiovascular disease risk markers in first episode psychosis subjects
Schizophr. Res.
(2008) - et al.
Olanzapine and haloperidol in first episode psychosis: two-year data
Schizophr. Res.
(2006) - et al.
Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial
Lancet
(2008) - et al.
Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials
Schizophr. Res.
(2003) - et al.
Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease? Am
J. Cardiol.
(2005) - et al.
Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naive population
Schizophr. Res.
(2008) - et al.
Weight gain and lipid metabolic abnormalities induced by olanzapine in first-episode, drug-naive patients with psychotic disorders
Schizophr. Res.
(2005) Scale for the Assessment of Negative symptoms (SANS)
(1983)Scale for the Assessment of Positive Symptoms (SAPS)
(1984)- et al.
A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse
J. Clin. Psychopharmacol.
(2003)